Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibacterials - Vaxart

Drug Profile

Research programme: antibacterials - Vaxart

Alternative Names: Benzothiazole urea based inhibitors -Vaxart; CDI-538 series antibacterials - Prolysis; CDI-936 series antibacterials - Prolysis; GYR-767 series antibacterials - Prolysis; PC-190708; PC-190723

Latest Information Update: 16 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prolysis
  • Developer Aviragen Therapeutics
  • Class 2 ring heterocyclic compounds; Amides; Small molecules
  • Mechanism of Action Cell division inhibitors; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections; Clostridium difficile infections; Pneumonia; Skin and soft tissue infections; Staphylococcal infections

Most Recent Events

  • 13 Feb 2018 Aviragen Therapeutics has merged with Vaxart forming Vaxart
  • 29 Jan 2018 Discontinued - Preclinical for Bacterial infections in Australia (IV)
  • 29 Jan 2018 Discontinued - Preclinical for Bacterial infections in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top